JP2018537418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537418A5 JP2018537418A5 JP2018519903A JP2018519903A JP2018537418A5 JP 2018537418 A5 JP2018537418 A5 JP 2018537418A5 JP 2018519903 A JP2018519903 A JP 2018519903A JP 2018519903 A JP2018519903 A JP 2018519903A JP 2018537418 A5 JP2018537418 A5 JP 2018537418A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- patient
- pharmaceutical composition
- immunoglobulin
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021048873A JP7389077B2 (ja) | 2015-10-19 | 2021-03-23 | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
| JP2023116721A JP2023134701A (ja) | 2015-10-19 | 2023-07-18 | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
| JP2025168405A JP2026010006A (ja) | 2015-10-19 | 2025-10-06 | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562243381P | 2015-10-19 | 2015-10-19 | |
| US62/243,381 | 2015-10-19 | ||
| PCT/IB2016/056166 WO2017068472A1 (en) | 2015-10-19 | 2016-10-14 | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021048873A Division JP7389077B2 (ja) | 2015-10-19 | 2021-03-23 | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537418A JP2018537418A (ja) | 2018-12-20 |
| JP2018537418A5 true JP2018537418A5 (enExample) | 2019-09-12 |
| JP6858766B2 JP6858766B2 (ja) | 2021-04-14 |
Family
ID=57223732
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519903A Active JP6858766B2 (ja) | 2015-10-19 | 2016-10-14 | インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
| JP2021048873A Active JP7389077B2 (ja) | 2015-10-19 | 2021-03-23 | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
| JP2023116721A Withdrawn JP2023134701A (ja) | 2015-10-19 | 2023-07-18 | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
| JP2025168405A Pending JP2026010006A (ja) | 2015-10-19 | 2025-10-06 | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021048873A Active JP7389077B2 (ja) | 2015-10-19 | 2021-03-23 | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
| JP2023116721A Withdrawn JP2023134701A (ja) | 2015-10-19 | 2023-07-18 | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
| JP2025168405A Pending JP2026010006A (ja) | 2015-10-19 | 2025-10-06 | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190330328A1 (enExample) |
| EP (1) | EP3365011A1 (enExample) |
| JP (4) | JP6858766B2 (enExample) |
| KR (1) | KR20180064415A (enExample) |
| CN (1) | CN108367074A (enExample) |
| AU (4) | AU2016342578A1 (enExample) |
| CA (1) | CA3002622A1 (enExample) |
| HK (1) | HK1251481A1 (enExample) |
| IL (2) | IL297775A (enExample) |
| RU (2) | RU2020124276A (enExample) |
| WO (1) | WO2017068472A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2665954C1 (ru) | 2010-10-08 | 2018-09-05 | Новартис Аг | Способы лечения псориаза с использованием антагонистов il-17 |
| TWI616204B (zh) | 2010-11-05 | 2018-03-01 | 諾華公司 | Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP6858766B2 (ja) * | 2015-10-19 | 2021-04-14 | ノバルティス アーゲー | インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
| MY207225A (en) | 2015-10-27 | 2025-02-06 | UCB Biopharma SRL | Methods of treatment using anti-il-17a/f antibodies |
| EP3641813A4 (en) | 2017-06-18 | 2021-04-21 | Kindred Biosciences, Inc. | IL17A ANTIBODIES AND ANTAGONISTS FOR USE IN VETERINARY MEDICINE |
| CA3071337A1 (en) | 2017-08-15 | 2019-02-21 | Kindred Biosciences, Inc. | Igg fc variants for veterinary use |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| EP4591879A3 (en) | 2019-01-31 | 2025-10-22 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
| EP3963541A1 (en) * | 2019-04-29 | 2022-03-09 | UCB Biopharma SRL | Medical image analysis system and method for identification of lesions |
| CA3155108A1 (en) * | 2019-09-20 | 2021-03-25 | Novartis Ag | Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists |
| CA3196991A1 (en) * | 2020-11-05 | 2022-05-12 | Florence Wing Ling Tsui | Methods for systematically assessing local inflammation and active repair |
| EP4471427A1 (en) * | 2023-05-31 | 2024-12-04 | Centre Hospitalier Universitaire De Nice | Biomarker for spondyloarthitis diagnostic and response to treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CN101374864A (zh) | 2006-01-31 | 2009-02-25 | 诺瓦提斯公司 | 用于靶向癌症的il-17拮抗性抗体 |
| TWI616204B (zh) * | 2010-11-05 | 2018-03-01 | 諾華公司 | Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途 |
| KR20150010709A (ko) * | 2012-04-20 | 2015-01-28 | 노파르티스 아게 | Il-17 길항제를 사용하는 강직성 척추염의 치료 방법 |
| JP6858766B2 (ja) * | 2015-10-19 | 2021-04-14 | ノバルティス アーゲー | インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
-
2016
- 2016-10-14 JP JP2018519903A patent/JP6858766B2/ja active Active
- 2016-10-14 KR KR1020187010627A patent/KR20180064415A/ko not_active Ceased
- 2016-10-14 HK HK18111096.0A patent/HK1251481A1/zh unknown
- 2016-10-14 RU RU2020124276A patent/RU2020124276A/ru unknown
- 2016-10-14 CA CA3002622A patent/CA3002622A1/en active Pending
- 2016-10-14 RU RU2018118177A patent/RU2728710C2/ru active
- 2016-10-14 EP EP16790436.6A patent/EP3365011A1/en active Pending
- 2016-10-14 US US15/766,043 patent/US20190330328A1/en not_active Abandoned
- 2016-10-14 IL IL297775A patent/IL297775A/en unknown
- 2016-10-14 CN CN201680072561.XA patent/CN108367074A/zh active Pending
- 2016-10-14 WO PCT/IB2016/056166 patent/WO2017068472A1/en not_active Ceased
- 2016-10-14 AU AU2016342578A patent/AU2016342578A1/en not_active Abandoned
- 2016-10-14 IL IL257723A patent/IL257723B2/en unknown
-
2019
- 2019-09-30 AU AU2019240551A patent/AU2019240551A1/en not_active Abandoned
-
2021
- 2021-03-23 JP JP2021048873A patent/JP7389077B2/ja active Active
- 2021-10-01 AU AU2021240290A patent/AU2021240290A1/en not_active Abandoned
-
2023
- 2023-07-18 JP JP2023116721A patent/JP2023134701A/ja not_active Withdrawn
-
2024
- 2024-04-05 US US18/628,097 patent/US20250066466A1/en active Pending
- 2024-12-04 AU AU2024278118A patent/AU2024278118A1/en active Pending
-
2025
- 2025-10-06 JP JP2025168405A patent/JP2026010006A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sieper et al. | Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials | |
| Van der Heijde et al. | Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial | |
| JP7389077B2 (ja) | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 | |
| CN106413748A (zh) | 用于类风湿性关节炎治疗的组合物及使用该组合物的方法 | |
| JP2022177132A (ja) | 精神障害の治療 | |
| AU2015313827B2 (en) | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| So et al. | An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| AU2011293554A1 (en) | Treatment for neoplastic diseases | |
| JP2015172060A5 (enExample) | ||
| TW202126329A (zh) | 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法 | |
| Woodrick et al. | IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions. | |
| Lourenço et al. | Polymyalgia rheumatica after ChAdOx1 nCov-19 vaccine: a case report | |
| JP2023527200A5 (enExample) | ||
| Umeda et al. | A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment | |
| Adelsten et al. | Safe and effective tumour necrosis factor-α inhibitor (etanercept) treatment of chronic episodic arthritis in a patient with cystic fibrosis | |
| TW202246329A (zh) | 抗il-17抗體治療自體免疫性疾病和炎症的方法 | |
| Wiland et al. | FRI0087 Efficacy, safety, and immunogenicity results of the switch from reference adalimumab (refadl) to Sandoz biosimilar adalimumab (gp2017, sdz-adl) from ADMYRA phase 3 study in patients with moderate-to-severe rheumatoid arthritis (RA) | |
| CN115515978A (zh) | 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体 | |
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| Yokota et al. | Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan | |
| Edwards et al. | Fri0088 safety, immunogenicity and efficacy of the proposed biosimilar MSB11022 (modified formulation) compared with adalimumab reference product in patients with moderately to severely active rheumatoid arthritis: AURIEL-RA, a randomised, double-blind, phase III study | |
| Carolina et al. | Polymyalgia Rheumatica After ChAdOx1 nCov-19 Vaccine: A Case Report | |
| Walsh et al. | O06 Improvements in pain, function and health status with subcutaneous tanezumab compared with placebo in patients with OA: pooled analysis of two randomized controlled trials | |
| TW202540166A (zh) | 用於治療自體免疫性疾病／自體免疫性病症的ｃｄ１９選擇性ｔ細胞接合分子 |